Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22353042 | 0.97 | ELANE (0.48) | ELANEKMT2AATMLMNAGAA | |
| SCHEMBL22345623 | 0.91 | ELANE (0.49) | ELANEKMT2AATMLMNAMAPT | |
| SCHEMBL22353033 | 0.89 | ELANE (0.40) | ELANEKMT2AATMMAPTBACE1 | |
| SCHEMBL24377891 | 0.88 | ELANE (0.44) | ELANEKMT2AATMLMNAGAA | |
| SCHEMBL22352935 | 0.87 | ELANE (0.41) | ELANEKMT2AATMMAPTBACE1 | |
| SCHEMBL22353031 | 0.87 | CFD (0.40) | ELANEKMT2AATMGAAMAPT | |
| SCHEMBL22352941 | 0.85 | ELANE (0.44) | ELANEKMT2AATMMAPTTDP1 | |
| SCHEMBL22353034 | 0.85 | ELANE (0.51) | ELANEKMT2AATMLMNAMAPT | |
| SCHEMBL22352782 | 0.85 | ELANE (0.36) | ELANEKMT2AATMBACE1 | |
| SCHEMBL22352922 | 0.85 | ELANE (0.40) | ELANEKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924447-B1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| WO-2020165394-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | LPXN, VCL, LCP1 | ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885 |
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | LPXN, VCL, LCP1 | ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.